In ischemic LV dysfunction, adding PCI to medical therapy did not reduce a composite of death or aborted sudden death

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Clinical Trials

Background:

• Ischemic left ventricular dysfunction (ILVD) is a significant cause of heart failure.
• Percutaneous revascularization aims to improve blood flow to the heart muscle in patients with coronary artery disease.
• The benefit of revascularization in ILVD patients with severely reduced ejection fraction remains controversial.

Purpose of the Study:

• To investigate the impact of percutaneous coronary intervention (PCI) on the incidence of death and serious arrhythmias in patients with ILVD.
• To analyze prespecified outcomes from the REVIVED-BCIS2 trial.

Main Methods:

• Prespecified analysis of the REVIVED-BCIS2 randomized controlled trial.
• Inclusion of patients with ILVD (left ventricular ejection fraction ≤35%) and significant coronary artery disease.
• Comparison of outcomes between patients undergoing PCI plus optimal medical therapy versus optimal medical therapy alone.

Main Results:

• Percutaneous revascularization did not significantly reduce the primary composite endpoint of all-cause death or new/worsening heart failure.
• There was no significant difference in the rate of serious arrhythmias (ventricular tachycardia or fibrillation) between the PCI and medical therapy groups.
• The study found no significant benefit of revascularization on mortality or arrhythmia burden in this specific patient population.

Conclusions:

• Percutaneous revascularization in patients with ILVD and viable myocardium does not reduce the risk of death or serious arrhythmias.
• These findings challenge the routine use of revascularization in patients with ILVD and severely impaired left ventricular function.
• Optimal medical therapy remains the cornerstone of management for these high-risk patients.